NEJM· Thomas D. NortonRegeneron Pharmaceuticals, Tarrytown, NYJorg TaubelRichmond Pharmacology, LondonGavin H. ImperatoSonya Aziz-ZamanJane WitkinJutta MillerKusha A. MohammadiShunguang WangTerri SwansonMadison StomsXiping ChengJessica D’AntonioShehla HabibDavid WorkmanJustin ChoYogesh PatelVidya XavierChao ChenDavid J. SmithSean SmithSusana PereiraDonato ForlenzaJoette PindarMeredith CrosbyShawn FidottaMauricio LealFady TaniosViktoria GusarovaMark SleemanJennifer HamiltonJohn DavisDinko Gonzalez TrotterRong LiuBret MusserEd CoxNed BraunsteinNiek VerweijLuca A. LottaGeorge D. YancopoulosAris BarasGary A. HermanDavid J. Ledererfor the ALN-CIDEB-NASH-2486 Study Investigators, Regeneron Genetics Center (RGC), Geisinger Health System–RGC DiscovEHR Collaboration, Penn Medicine Biobank, Colorado Center for Personalized Medicine, Mayo Clinic–RGC Project Generation, Malmö Diet and Cancer Study, Indiana University School of Medicine (Indiana-CLDB), UCLA Health–RGC ATLAS Collaboration, Mount Sinai Million Health Discoveries Program, and the University of Texas Southwestern, Dallas Biobank*Regeneron Pharmaceuticals, Tarrytown, NY·· 9 天前精选AI 评分62
靶向肝脏的CIDEB siRNA在MASLD成人患者中的研究
A Liver-Targeted CIDEB siRNA in Adults with MASLD
AI 导读
NEJM刊出由Regeneron主导的研究,评估靶向肝脏的CIDEB siRNA在MASLD成人患者中的应用,研究团队包括ALN-CIDEB-NASH-2486研究者和多个生物样本库协作方。当前仅有标题与作者信息,尚无具体疗效或安全性数据。
来源:NEJM · nejm.org